These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6073947)

  • 21. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor IX concentrates for clinical use.
    Thompson AR
    Semin Thromb Hemost; 1993; 19(1):25-36. PubMed ID: 8456321
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemophilia.
    Kashyap R; Choudhry VP
    Indian Pediatr; 2000 Jan; 37(1):45-53. PubMed ID: 10745388
    [No Abstract]   [Full Text] [Related]  

  • 26. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards gene therapy for haemophilia B using primary human keratinocytes.
    Gerrard AJ; Hudson DL; Brownlee GG; Watt FM
    Nat Genet; 1993 Feb; 3(2):180-3. PubMed ID: 8499952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
    Aledort LM; Cohen M; Hilgartner M; Lipton R
    Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
    [No Abstract]   [Full Text] [Related]  

  • 29. [The successful use of FEIBA for treatment of intracranial hemorrhage in a patient of hemophilia B with inhibitor].
    Taki M; Inagaki M; Tomita Y; Miura T; Saito N; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Aug; 26(8):1300-5. PubMed ID: 3877831
    [No Abstract]   [Full Text] [Related]  

  • 30. Haemophilia care in South Africa: 2004-2007 look back.
    Mahlangu JN;
    Haemophilia; 2009 Jan; 15(1):135-41. PubMed ID: 18700842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B.
    Walker JA; Dixon N; Gururangan S; Thornburg C
    Haemophilia; 2008 Mar; 14(2):387-9. PubMed ID: 18194312
    [No Abstract]   [Full Text] [Related]  

  • 34. An unusual cause of acute torticollis.
    Sankar J; Srinivasan A; Ramakrishnan V; Balasubramaniam C
    Clin Pediatr (Phila); 2009 Sep; 48(7):784-5. PubMed ID: 19224866
    [No Abstract]   [Full Text] [Related]  

  • 35. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter: Home treatment for haemophilia.
    Leven LB
    Lancet; 1975 Jan; 1(7900):230. PubMed ID: 47470
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of hemophilia B with 15 nm filtered factor IX-LFB].
    Derlon A
    Presse Med; 1998 Apr; 27(15):740-1. PubMed ID: 9767918
    [No Abstract]   [Full Text] [Related]  

  • 38. Haemophilia B caused by a missense mutation in the prepeptide sequence of factor IX.
    Green PM; Mitchell VE; McGraw A; Goldman E; Giannelli F
    Hum Mutat; 1993; 2(2):103-7. PubMed ID: 8318985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland.
    Prowse CV; Cash JD
    Br J Haematol; 1981 Jan; 47(1):91-104. PubMed ID: 7437348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.